Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The ROADMAP project launches its Data Cube. The Cube offers a dynamic overview of the ‘landscape’ of data availability in Europe for Alzheimer’s disease research.

Funded through the Innovative Medicines Initiative, the public-private Real world outcomes across the Alzheimer's Disease spectrum for better care: Multi-modal data Access Platform (ROADMAP) project brought together 26 organisations led by Novartis and coordinated by the University of Oxford.

One of the partnership's main aspirations was to support the identification and integration of realworld data across multiple sources and countries. Through that, it intended to support opportunities for the development of evidence for the reimbursement and access of new technologies for the treatment of Alzheimer's disease (AD), ultimately aiming to drive healthcare systems towards better care and data capture.

The consortium therefore collaboratively developed this 3D 'heat map' assessment. It allows the visualisation of the different data sources and how they are able to capture different AD-outcomes together with their relevance for the different disease stages. Users can switch between the perspectives of people with dementia, carers and health professionals. Enabling the visualisation of the AD-related data availability in different types of European data
sources and the intrinsic gaps, has proven to be a powerful tool for the design, planning and validation of the models and strategies used to guide future recommendations to enhance AD research.

Through these efforts, ROADMAP helps address the challenge of how best to inform clinical and health-policy decisions by studying how to build a population-based integrated data environment and enabling its visualisation. The online version of the Data Cube is available here: https://datacube.roadmap-alzheimer.org.

The Data Cube is an important outcome of the ROADMAP project as it provides a much needed, overarching picture of priority outcomes, across the disease stages, and whether data is available. It helps to identify gaps in the evidence and provides a useful tool for regulatory and HTA purposes. - Dr Jacoline Bouvy, Senior Scientific Adviser, NICE

Similar stories

Healthy Start, Happy Start Study

Research Highlights

Healthy Start, Happy start is a randomised controlled trial that tested the clinical- and cost-effectiveness of a brief parenting programme - Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP-SD).

Oxford Awarded Major Funding to Probe Childhood Poverty and Social Inequalities

Strategic Developments

Ground-breaking multi-disciplinary research is to be launched today by the University of Oxford into the impact of poverty and social inequalities in early childhood, thanks to major funding from the Leverhulme Trust.

New Way of Understanding Dissociation Could Improve Patient Care

Research Highlights

New research has developed a novel measure of dissociative experiences that share a subjective 'felt sense of anomaly'. This new approach could revolutionise how clinicians understand dissociative experiences across a range of mental health disorders, and how they work with patients with dissociation in the future.

David Paterson on the real value of research

Strategic Developments

Head of DPAG David Paterson joins Lord David Willets, Dame Ottoline Leyser and Priya Guha in discussing the future priorities for UK Research and Innovation (UKRI) - summaries are now published in The Foundation for Science and Technology Journal.

New Analysis Challenges Guidelines on Treating Anorexia Nervosa

Research Highlights

A new analysis, published in The Lancet Psychiatry, has shown a lack of strong evidence to support current guidance on psychological therapies for treating anorexia nervosa over expert treatment as usual.